稳定性COPD患者的ICS IgE引导使用:现实世界的观察性研究
Ziwei Zhou1, Yu Tao1, Siyi Zhou1
1Department of Respiratory and Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
COPD
|October 30, 2025
概括
总血清IgE (T-IgE) 可以指导慢性阻塞性肺病 (COPD) 的吸入性皮质类固醇 (ICS) 治疗. 高水平的T-IgE在COPD患者预测减少恶化与ICS治疗,提供个性化的治疗策略.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 生物标志物发现发现
背景情况:
- 慢性阻塞性肺病 (COPD) 恶化严重影响患者的发病率和医疗费用.
- 个性化医疗方法对于优化COPD治疗疗效至关重要.
- 确定可靠的生物标志物以指导治疗,如吸入性皮质类固醇 (ICS),仍然是一个持续的挑战.
研究的目的:
- 研究全血清IgE (T-IgE) 作为指导稳定性COPD患者个性化ICS治疗的生物标志物的实用性.
- 确定T-IgE水平是否可以预测ICS治疗对减少COPD恶化反应的反应.
主要方法:
- 追溯和前性队列研究,涉及稳定的COPD患者 (n=1776).
- 基于基线T-IgE水平的患者分层 (切断值在100和76 IU/mL).
- 倾向性得分匹配和多变量回归分析,以评估ICS对恶化风险的影响.
主要成果:
- 患有T-IgE≥100 IU/mL的COPD患者表现出明显增加的恶化风险.
- 在高T-IgE亚组 (T-IgE ≥100 IU/mL) 中,ICS治疗显著降低了恶化风险.
- 在T-IgE<100 IU/mL的患者中没有观察到ICS的显著益处;T-IgE稳定性和与肺功能相关性也被分析.
结论:
- 总血清IgE水平与COPD恶化密切相关.
- 高T-IgE水平可以识别COPD患者从ICS治疗中受益,从而实现个性化治疗策略.
- T-IgE显示出作为一个稳定的生物标志物的潜力,用于指导ICS在COPD管理中的使用.
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
692
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
692
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K
01:23Inhaled Medications
679
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
679
01:29Chronic Obstructive Pulmonary Disease-V: Management
3.1K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
3.1K
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
3.1K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
3.1K
01:30Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K